{"id":"W3136768966","doi":"10.1016/j.clgc.2021.03.006","title":"Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University of Calgary","funders":"Mailman School of Public Health, Columbia University; Pfizer Canada; Genentech; Astellas Pharma; Bristol-Myers Squibb Canada; Eisai; Ipsen; Astellas Pharma Canada; Roche; EMD Serono; Novartis; AstraZeneca; Amgen; Pfizer; Exelixis; Meso Scale Diagnostics; Sanofi; MedImmune; Merck; GlaxoSmithKline","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Oncology; Internal medicine; Clinical Oncology; Kidney cancer; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002401639,0.0004403181,0.002212445,0.0002198102,0.00006766666,0.00001209825,0.0002167184,0.0001837361,0.0003557501],"category_scores_gemma":[0.000177463,0.0003333488,0.0006994082,0.0007591431,0.0002285418,0.0000959922,0.0001829424,0.0008735637,0.000009788732],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004304257,"about_ca_system_score_gemma":0.001704849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003773406,"about_ca_topic_score_gemma":0.0008604332,"domain_scores_codex":[0.9924249,0.003434856,0.00207524,0.0009842278,0.0005633279,0.0005174535],"domain_scores_gemma":[0.9945268,0.00318237,0.0005386118,0.0009229432,0.0005018841,0.0003274101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01768842,0.01926063,0.9462171,0.000221536,0.0009796487,0.005079681,0.0001843599,0.00002788317,0.0006838887,0.000001044653,0.00005332709,0.009602474],"study_design_scores_gemma":[0.04680541,0.02922594,0.918282,0.0002498833,0.000759115,0.00001067572,0.0002826877,0.000007536997,0.003787118,0.00001383901,0.0002940451,0.0002817294],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933753,0.001655283,0.000003904448,0.00005429747,0.0008046653,0.002256285,0.0000385362,0.00002865072,0.001783097],"genre_scores_gemma":[0.9973615,0.0003254737,0.0006479533,0.0001757011,0.0002969308,0.0003113688,0.0001245106,0.00008210428,0.0006744025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02911699,"threshold_uncertainty_score":0.9999118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0731584245030044,"score_gpt":0.4054384180125898,"score_spread":0.3322799935095854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}